The most common blood type among the population in the United States is O-positive. Around 53 percent of the Latino-American population in the U.S. has blood type O-positive, while only around 37 percent of the Caucasian population has this blood type. The second most common blood type in the United States is A-positive. Around 33 percent of the Caucasian population in the United States has A-positive blood type. Blood type O-negative Those with blood type O-negative are universal donors as this type of blood can be used in transfusions for any blood type. O-negative blood type is most common in the U.S. among Caucasian adults. Around eight percent of the Caucasian population has type O-negative blood, while only around one percent of the Asian population has this blood type. Only around seven percent of all adults in the United States have O-negative blood type. Blood Donations The American Red Cross estimates that someone in the United States needs blood every two seconds. However, only around three percent of age-eligible people donate blood yearly. The percentage of adults who donated blood in the United States has not fluctuated much for the past two decades. In 2021, around 15 percent of U.S. adults donated blood, the same share reported in the year 2003.

The eight main blood types are A+, A-, B+, B-, O+, O-, AB+, and AB-. The most common blood type in the United States is O-positive, with around 38 percent of the population having this type of blood. However, blood type O-positive is more common in Latino-Americans than other ethnicities, with around 53 percent of Latino-Americans with this blood type, compared to 47 percent of African Americans and 37 percent of Caucasians. Blood donation The American Red Cross estimates that every two seconds someone in the United States needs blood or platelets, highlighting the importance of blood donation. It was estimated that in 2021, around 6.5 million people in the U.S. donated blood, with around 1.7 million of these people donating for the first time. Those with blood type O-negative are universal blood donors, meaning their blood can be transfused for any blood type. Therefore, this blood type is the most requested by hospitals. However, only about seven percent of the U.S. population has this blood type. Blood transfusion Blood transfusion is a routine procedure that involves adding donated blood to a patient’s body. There are many reasons why a patient may need a blood transfusion, including surgery, cancer treatment, severe injury, or chronic illness. In 2021, there were around 10.76 million blood transfusions in the United States. Most blood transfusions in the United States occur in an inpatient medicine setting, while critical care accounts for the second highest number of transfusions.

This statistic displays the distribution of blood groups in the French population according to the Rh blood group system. It shows that less than *********** of French people have the blood group AB negative.

In 2023, the most common blood type in South Korea was A-positive, with about 33.8 percent of the total blood donations. It was followed by O-positive and B-positive.

According to Cognitive Market Research, the global blood group typing market size is USD XX million in 2023 and will expand at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.

The global blood group typing market will expand significantly by 8.8% CAGR between 2024 to 2031.
North America held the major market of more than XX% of the global revenue with a market size of USD XX million in 2023 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Europe accounted for a share of over XX% of the global market size of USD XX million.
Asia Pacific held a market of around XX% of the global revenue with a market size of USD XX million in 2023 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Latin America's market will have more than XX% of the global revenue with a market size of USD XX million in 2023 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2023 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The blood group typing industry is set to rise due to increased blood group ownership rates, rising awareness regarding blood group health, accelerated R&D in the blood group typing industry, and the rise of E-commerce. Increasing online retail channels further bolster demand, while cultural significance and investment appeal contribute to its enduring popularity.
The blood group typing market is driven by rising awareness regarding blood group health, accelerated R&D in the blood group typing industry, and the rise of E-commerce.
Antibody Screenings are anticipated to form the majority of blood group owners in the years to come.

Current Scenario of the Blood Group Typing Market

Key Drivers of the Blood Group Typing Market

The growing incidence of chronic illnesses and the increase in surgical operations necessitates the need for blood donations

The demand for blood has grown as chronic diseases and the surgical procedures necessary to treat them have become more common. Blood transfusions are typically necessary for patients with chronic illnesses to manage their symptoms, and large volumes of blood are required for surgical procedures, particularly major surgeries, to ensure safe and effective results. As a result, the need for blood has steadily increased within the healthcare system, which has led to a rise in blood donation rates. The market is anticipated to benefit from this. To treat patients with chronic illnesses and those having difficult surgical operations, the American National Red Cross (2023) estimates that every day, over 29,000 units of red blood cells are required in US hospitals and emergency rooms. For instance, according to the National Center for Biotechnology Information, the number of people 50 years of age and older who have at least one chronic illness is predicted to rise from 71.522 million in 2020 to 142.66 million in 2050, a 99.5% increase.

Source- https://pubmed.ncbi.nlm.nih.gov/36711415/#:~:text=Of%20the%20population%2050%20years,to%2014.968%20million%20in%202050.

Blood group typing is a necessary test that establishes the Rh factor and the level of blood compatibility between the donor and the recipient prior to blood transfusions. Thus, the need for blood donations is a result of the rising prevalence of chronic illnesses and the rise in surgical procedures.

Blood Donation rates have necessitated the need for Blood Group Typing

Global blood donation rates have significantly increased over time. The need for transfusion procedures such as blood type detection and cross-matching has surged due to a rise in voluntary blood donations. The National Health Service Blood and Transplant (NHSBT) receives over 1.5 million voluntary blood donations annually, which are processed by the government before being given to hospitals and patients in need, according to an article published by the European Blood Alliance (EBA) (2019–2022).

Source- https://www.nhsbt.nhs.uk/who-we-are/a-history-of-donation-transfusion-and-transplantation/

NHSBT supplies hospitals in England with a secure and dependable supply of blood components, diagnostic services, and stem cell treatments. To do this, it depends on 1...

Association of ABO blood types with depression prevalence.

ABO allele frequencies and resultant ABO phenotypes were consistent with known prevalence in the Caucasian population. [26] There is no significant difference in blood type distribution amongst mild and severe patients, or in any subgroup analysis (see Text S1) by Fisher exact test. (n = 778, p = 0.446)

The Rhesus (Rh) blood group system (including the Rh factor) is the second most important blood group system after the ABO blood group system. The Rh blood type was first discovered in 1937 by Karl Landsteiner and Alexander S. Wiener who named it after the rhesus macaque whose RBCs were used to generate the rabbit immune serum that first detected the human blood group system. Subsequent studies by them and Philip Levine and Rufus Stetson identified the antigen that induced this immunization as the "Rh factor" and also its association with hemolytic disease of the newborn (Levine & Stetson 1984, Landsteiner & Wiener 1941). Of the 50 defined Rh blood group antigens, five (D, C/c and E/e) are the major types expressed by the RHD and RHCE genes in the RH gene complex. Rh antigens are expressed on red cell (RBC) membranes in association with other membrane proteins and this whole complex interacts with the spectrin-based skeleton and contributes to the maintenance of the mechanical properties of the RBC membrane (Van Kim et al. 2006).

The RHD gene produces the D antigen, the most immunogenic Rh antigen. The term "Rh factor" refers only to the D antigen; Rh positive (Rh+) individuals have the D antigen on their RBC membranes whereas Rh negative (Rh-) individuals don't. Humans are not born with antibodies towards the D antigen in their blood, they have to be exposed to it (through blood transfusion or placental exposure during pregnancy) at some point in their lives before antibodies are made against it. Once exposed, however, Rh+ individuals remain sensitive for the rest of their lives. Importantly, if individuals are Rh+ and are exposed to Rh- blood, no immune response is mounted. Anti-D antibodies are only seen if an individual is lacking the D antigen (Rh-) and is exposed to Rh+ blood. The RHCE gene produces polypeptides with C/c and E/e antigens.

These polypeptides are the core components of their respective antigens but by themselves are devoid of the immunoreactivity which defines the Rh antigens. The remaining antigens are produced by partial deletion, recombination, mutation, or polymorphisms of one or both RHD and RHCE genes (Cartron 1999). Together, these antigens form the most complex and polymorphic blood group system based on the multitude of phenotypes that can be expressed on the RBC surface. The Fisher-Race system, the nomenclature used most commonly, uses the CDE system to depict the notation of Rh genotypes (Race 1948). The most common group of 3 genes inherited is CDe with ce (D negative) being the second most common. Rh genotyping is used in blood transfusion, paternity testing and to determine the risk of hemolytic disease of the newborn.

ABO Blood Type Test Kit Market Outlook

The global ABO blood type test kit market size was valued at USD 780 million in 2023 and is projected to reach USD 1.2 billion by 2032, growing at a CAGR of 4.8% during the forecast period. The market for ABO blood type test kits is experiencing robust growth primarily driven by increasing demand for blood transfusion services, advancements in diagnostic technologies, and the rising prevalence of chronic diseases necessitating blood type testing. These factors contribute significantly to the market's expansion and its optimistic outlook.

One of the primary growth factors for the ABO blood type test kit market is the increasing number of surgical procedures and trauma cases worldwide, which demand immediate and accurate blood typing. Additionally, the growing awareness about the importance of blood typing in organ transplantation and prenatal testing further propels the market. The surge in blood donation drives and the need for efficient blood bank management systems, which rely heavily on accurate blood type testing, also significantly contribute to market growth.

Technological advancements in diagnostic techniques, such as the development of rapid test kits that offer quick and reliable results, are another critical driver of market expansion. These innovations have made blood typing more accessible and convenient, particularly in remote and underserved areas. The rising adoption of point-of-care testing, which allows for blood type determination outside traditional laboratory settings, is also enhancing the market's growth prospects.

The increasing prevalence of chronic diseases, such as cancer and kidney disorders, which often require regular blood transfusions, is a significant factor fueling the demand for ABO blood type test kits. Moreover, the aging global population, which is more susceptible to various medical conditions requiring blood transfusions, contributes to the sustained demand for these kits. Public health initiatives and government policies promoting regular health check-ups and blood donation are also playing a crucial role in driving the market forward.

From a regional perspective, North America holds a dominant position in the ABO blood type test kit market due to its well-established healthcare infrastructure, high awareness levels, and significant investments in healthcare technologies. Europe follows closely, driven by similar factors along with a strong focus on research and development. The Asia Pacific region is expected to witness the fastest growth, attributed to its large population base, increasing healthcare expenditures, and rising awareness about blood-related health issues. Other regions, including Latin America and the Middle East & Africa, are also showing promising growth potential due to improving healthcare facilities and increasing government initiatives.

Product Type Analysis

The ABO blood type test kit market is segmented by product type into rapid test kits and laboratory test kits. Rapid test kits are designed for quick and efficient blood typing, providing results in a matter of minutes. These kits are particularly useful in emergency situations, field settings, and for point-of-care testing. The demand for rapid test kits is driven by their ease of use, minimal training requirements, and the ability to deliver immediate results, making them highly suitable for use in various non-laboratory settings.

Laboratory test kits, on the other hand, are designed for use in clinical laboratories and provide highly accurate and reliable results. These kits are typically used in hospitals, diagnostic laboratories, and blood banks where precision is crucial. The demand for laboratory test kits is driven by the increasing number of diagnostic procedures and the need for accurate blood type determination in critical medical situations. These kits often employ advanced technologies such as gel cards and microplates, contributing to their high accuracy and reliability.

The rapid test kits segment is expected to witness significant growth during the forecast period due to the increasing adoption of point-of-care testing and the rising need for quick and efficient blood type determination in emergency and remote settings. The convenience and speed offered by rapid test kits are making them increasingly popular among healthcare providers and individual consumers alike. Additionally, advancements in rapid testing technologies are further enhancing the accuracy and reliability of these kits, contributing to their growing demand.

ABO blood groups are known to influence the plasma level of von Willebrand factor (VWF), but little is known about the relationship between ABO and coagulation factor VIII (FVIII). We analyzed the influence of ABO genotypes on VWF antigen, FVIII activity, and their quantitative relationship in 11,673 participants in the Atherosclerosis Risk in Communities (ARIC) study. VWF, FVIII, and FVIII/VWF levels varied significantly among O, A (A1 and A2), B and AB subjects, and the extent of which varied between Americans of European (EA) and African (AA) descent. We validated a strong influence of ABO blood type on VWF levels (15.2%), but also detected a direct ABO influence on FVIII activity (0.6%) and FVIII/VWF ratio (3.8%) after adjustment for VWF. We determined that FVIII activity changed 0.54% for every 1% change in VWF antigen level. This VWF-FVIII relationship differed between subjects with O and B blood types in EA, AA, and in male, but not female subjects. Variations in FVIII activity were primarily detected at low VWF levels. These new quantitative influences on VWF, FVIII and the FVIII/VWF ratio help understand how ABO genotypes differentially influence VWF, FVIII and their ratio, particularly in racial and gender specific manners.

Top row: unadjusted values; bottom row (shaded): values adjusted for age, smoking, BMI, diabetes, and hypertension (race and gender were also included for overall population; race in the gender-specific analyses and gender in the race-specific analyses)Geometric Mean (95% CI) of FVIII/VWF Ratio in ABO Blood Groups*.

BackgroundThe goal is to determine the delays and reduced rates of kidney transplant (KTx) for the Indigenous Americans and variables predictive of these outcomes at a large single transplant center.Methods300 Indigenous Americans and 300 non-Hispanic white American patients presenting for KTx evaluation from 2012–2016 were studied.ResultsCompared to whites, the Indigenous Americans had the following: more diabetes, dialysis, physical limitation and worse socioeconomic characteristics(p

The global blood group typing market is experiencing robust growth, driven by the increasing prevalence of blood transfusions and the rising demand for accurate and rapid blood typing methods. Technological advancements, such as the adoption of automated and high-throughput systems, are significantly improving the efficiency and accuracy of blood typing procedures, leading to faster turnaround times and reduced errors. Furthermore, the growing prevalence of chronic diseases requiring frequent blood transfusions and the increasing number of surgical procedures are contributing to market expansion. The market is segmented by type (manual, automated) and application (blood banks, hospitals, research). The automated segment is witnessing rapid growth due to its advantages in speed, accuracy, and efficiency. Hospitals and blood banks constitute the largest application segments, driven by their high volume of blood typing needs. Key players such as Agena Bioscience, Bio-Rad Laboratories, Danaher, Merck KGaA, and Ortho Clinical Diagnostics are strategically investing in research and development, mergers and acquisitions, and geographical expansion to solidify their market positions. This competitive landscape is fostering innovation and leading to the development of advanced blood typing technologies. The market's geographical distribution demonstrates significant regional variations. North America and Europe currently hold the largest market shares, attributed to well-established healthcare infrastructure, high adoption rates of advanced technologies, and increasing healthcare expenditure. However, developing economies in Asia-Pacific and the Middle East & Africa are exhibiting promising growth potential due to rising healthcare awareness, improving healthcare infrastructure, and increasing government initiatives aimed at enhancing healthcare services. While the market faces challenges such as stringent regulatory requirements and high costs associated with advanced technologies, the overall growth trajectory remains positive, fueled by unmet needs for efficient and precise blood typing solutions. We project sustained market expansion over the forecast period, driven by continued technological innovation and increasing healthcare demands globally.

Blood Group Typing Tool Market Outlook

The global blood group typing tool market size was valued at approximately $1.8 billion in 2023 and is expected to reach around $3.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% during the forecast period. This robust growth is driven by the increasing need for blood transfusions, advancements in medical diagnostics, and the rising prevalence of chronic diseases necessitating blood typing for treatment protocols.

One of the primary growth factors in the blood group typing tool market is the escalating demand for blood transfusions worldwide. With the rise in surgical procedures, trauma cases, and treatments for various medical conditions like cancer and anemia, there is an incessant need for accurate blood typing to ensure safe and compatible blood transfusions. This burgeoning demand is propelling the adoption of advanced blood group typing tools globally. Furthermore, the ongoing development of healthcare infrastructure in emerging economies is boosting the market's expansion.

Technological advancements in blood group typing methodologies are another significant driver of market growth. Innovations such as polymerase chain reaction (PCR)-based and microarray-based techniques have revolutionized the accuracy, speed, and reliability of blood typing. These advanced techniques minimize human error and provide rapid results, which are crucial in emergency medical scenarios. Additionally, the introduction of automated blood group typing instruments has further streamlined laboratory workflows, thus enhancing operational efficiency in healthcare settings.

The increasing awareness and initiatives by governmental and non-governmental organizations to promote voluntary blood donation have significantly impacted the market. Campaigns and education programs focusing on the importance of blood donation and precise blood group typing have led to an increase in blood donations. This, in turn, has fueled the demand for blood group typing tools in blood banks and transfusion centers. Moreover, the growing prevalence of chronic diseases that require regular blood transfusions has underscored the essential role of reliable blood typing tools in patient care.

In the realm of transplantation medicine, Serological Transplant Diagnostics play a pivotal role in ensuring the compatibility and success of organ transplants. These diagnostics are crucial in identifying and matching donor and recipient blood groups and tissue types, thereby minimizing the risk of transplant rejection. The integration of serological testing in transplant protocols has significantly improved patient outcomes by facilitating precise donor-recipient matching. As the demand for organ transplants continues to rise, the importance of serological diagnostics in transplantation cannot be overstated. This segment of diagnostics is witnessing advancements that enhance accuracy and speed, making them indispensable in modern healthcare settings.

Regionally, North America holds a significant share of the blood group typing tool market, driven by well-established healthcare infrastructure and high healthcare expenditure. Europe follows closely, supported by advancements in medical research and a robust regulatory framework. Emerging economies in the Asia Pacific region are witnessing rapid market growth due to increasing healthcare investments and improving diagnostic capabilities. The focus on enhancing healthcare services in Latin America and the Middle East & Africa is also contributing to the market's expansion, albeit at a slower pace compared to other regions.

Product Type Analysis

The blood group typing tool market is categorized into Kits, Reagents, Instruments, and Others. Kits constitute a substantial segment, as they offer convenience and ease of use in various clinical settings. They are pre-packaged with all necessary components to perform blood typing tests accurately and quickly. The rising demand for point-of-care testing and the increasing adoption of home healthcare solutions are driving the growth of this segment. Kits are particularly favored in remote or resource-limited areas where laboratory infrastructure may be lacking.

Reagents are another critical segment, encompassing various chemical substances used in blood group typing procedures. The consistent need for high-quality reagents to ensure accurate test results makes this segment indispensable

Blood Group Typing Market Outlook

The global blood group typing market size was valued at approximately USD 2.1 billion in 2023 and is projected to reach around USD 3.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period. This significant growth can be attributed to the increasing demand for safe blood transfusion, rising prevalence of chronic diseases, and advancements in technology related to blood group typing methodologies.

One of the primary growth factors of the blood group typing market is the rising incidence of chronic diseases and medical conditions that necessitate blood transfusion. Diseases such as cancer, hemophilia, and trauma cases require precise blood typing to ensure patient safety during transfusions. Furthermore, the growing number of surgical procedures, which often require blood transfusions, is another driving factor. The increasing adoption of blood group typing in prenatal screenings to prevent hemolytic disease in newborns is also contributing significantly to the market growth.

The advancements in technology are playing a crucial role in the blood group typing market. New methodologies such as polymerase chain reaction (PCR)-based techniques, microarray, and massively parallel sequencing have revolutionized the accuracy and efficiency of blood typing. These technological advancements reduce the risk of transfusion-related complications and improve patient outcomes. Moreover, the integration of artificial intelligence and machine learning in diagnostic processes is further enhancing the accuracy and speed of blood group typing, thereby fueling market growth.

Another critical factor contributing to the market growth is the increasing awareness and governmental initiatives promoting voluntary blood donation. Governments and NGOs are undertaking various programs to educate the public about the importance of blood donation and the need for safe transfusion practices. These initiatives are resulting in increased blood donation rates, which in turn is driving the demand for advanced blood group typing techniques. Additionally, the rising healthcare expenditure in developing countries is enabling the adoption of sophisticated blood typing technologies, further propelling market growth.

Regionally, North America is expected to hold the largest market share due to the high prevalence of chronic diseases, advanced healthcare infrastructure, and significant investment in research and development. Europe is also anticipated to witness substantial growth owing to the increasing number of blood donations and advancements in healthcare technology. The Asia Pacific region is projected to experience the highest growth rate, driven by the large population base, increasing awareness about blood donation, and improving healthcare facilities. Latin America and the Middle East & Africa are also poised for growth, albeit at a slower pace, due to ongoing development in healthcare infrastructure and rising awareness.

Product Analysis

The product segment of the blood group typing market is categorized into instruments and reagents & kits. Instruments include automated and semi-automated analyzers used in blood typing, while reagents & kits encompass various antibodies, antigen kits, and other consumables necessary for blood typing procedures. The demand for instruments is driven by the need for high-throughput and accurate testing in hospitals and diagnostic laboratories. Automated analyzers are particularly gaining traction due to their ability to process large volumes of samples efficiently and with precision.

Reagents & kits hold a significant share in the market due to their recurring demand in routine blood typing tests. Continuous advancements and innovations in reagents, such as the development of monoclonal antibodies, are enhancing the accuracy and reliability of blood typing tests. The availability of a wide range of reagent kits designed for various blood typing techniques, including PCR-based and microarray methods, is further driving the market growth. Additionally, the increasing use of reagents in research laboratories for developing new blood typing methodologies is contributing to the segment's expansion.

The instruments segment is anticipated to witness considerable growth during the forecast period, driven by technological advancements and the rising adoption of automated systems in healthcare settings. The integration of advanced software and artificial intelligence in these instruments is further improving their efficiency and accura

The global blood group typing technology market is experiencing robust growth, driven by increasing demand for accurate and efficient blood transfusion procedures, rising prevalence of blood-related disorders, and the growing adoption of advanced diagnostic techniques. The market, estimated at $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching an estimated value of $4.2 billion by 2033. This expansion is fueled by several key factors. Technological advancements, such as the development of automated systems and point-of-care testing devices, are streamlining the blood typing process, improving accuracy, and reducing turnaround times. Furthermore, the increasing prevalence of chronic diseases requiring regular blood transfusions, coupled with a rising global population, significantly contributes to market growth. The shift towards personalized medicine and the need for precise blood type matching also contribute to market expansion. However, factors such as stringent regulatory requirements and the high cost associated with advanced technologies may pose challenges to market growth. The market is segmented based on technology (e.g., gel card technology, microplate technology, flow cytometry), product type (reagents, instruments, software), end-user (hospitals & blood banks, diagnostic laboratories), and geography. Key players such as Bio-Rad Laboratories, Merck Millipore, Ortho Clinical Diagnostics, and Danaher Corporation are driving innovation through continuous product development and strategic partnerships. The North American market currently holds a significant share, attributed to robust healthcare infrastructure and high adoption rates of advanced technologies. However, emerging markets in Asia-Pacific and Latin America are expected to witness significant growth in the coming years due to increasing healthcare expenditure and rising awareness about blood-related diseases. Overall, the blood group typing technology market is poised for continued expansion, driven by technological advancements, growing healthcare needs, and expanding global reach.

Snapshot img

Blood-Grouping Reagents Market Size 2025-2029

The blood-grouping reagents market size is valued to increase USD 611.8 million, at a CAGR of 8.8% from 2024 to 2029. Increasing prevalence of chronic disorders will drive the blood-grouping reagents market.

Major Market Trends & Insights

North America dominated the market and accounted for a 49% growth during the forecast period.
By End-user - Hospitals and blood banks segment was valued at USD 424.40 million in 2023
By Technique - PCR-based and microarray techniques segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 115.97 million
Market Future Opportunities: USD 611.80 million
CAGR from 2024 to 2029 : 8.8%

Market Summary

The market is a significant segment of the diagnostics industry, driven by the increasing prevalence of chronic disorders and the advancements in diagnostic devices. These reagents play a crucial role in identifying the blood types of donors and recipients for transfusions, ensuring compatibility and minimizing the risks associated with incompatible blood types. The market size was valued at USD 1.5 billion in 2020 and is expected to grow at a steady pace due to the rising demand for safe and efficient blood transfusions. The market's growth is underpinned by advancements in technology, including the development of rapid and automated blood-grouping systems, which offer faster and more accurate results. These advancements are expected to further boost market growth, enabling healthcare providers to offer faster and more efficient diagnostic services.
Additionally, the increasing incidence of chronic diseases, such as cancer and hemorrhagic disorders, necessitates a larger supply of safe blood, further fueling market growth. However, challenges persist, including the need for standardization and the high cost of advanced blood-grouping technologies. Despite these challenges, the market is expected to continue its expansion, driven by the growing need for safe and efficient blood transfusions.

What will be the Size of the Blood-Grouping Reagents Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Blood-Grouping Reagents Market Segmented ?

The blood-grouping reagents industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Hospitals and blood banks
  Clinical laboratories
  Academic and research institutes


Technique

  PCR-based and microarray techniques
  Assay-based techniques
  Massively parallel sequencing techniques
  Serology


Product

  Anti-sera reagents
  Red blood cell reagents
  Blood bank saline
  Others


Test Type

  Blood Grouping & Phenotyping
  Antibody Screening
  Cross-matching Tests
  Coombs Tests
  Antigen Typing
  Antibody Identification


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By End-user Insights

The hospitals and blood banks segment is estimated to witness significant growth during the forecast period.

The market is witnessing significant growth due to the escalating demand for blood typing in various healthcare applications. Hospitals and blood banks dominate the market landscape, accounting for the largest share, driven by the increasing need for blood transfusions in the treatment of chronic conditions and emergency cases. These reagents play a crucial role in diagnostic accuracy through agglutination reactions, hemolysis detection, and serological testing. Manufacturers focus on reagent manufacturing, concentration, and validation methods to ensure quality control and regulatory compliance. Technological advancements, such as enzyme immunoassay and automation systems, enhance test accuracy and reaction time. Monoclonal and polyclonal antibodies are integral to blood group typing, ensuring antibody specificity and minimizing false negatives and positives.

Reagent stability, incubation temperature, and sample preparation are essential factors in maintaining result interpretation and quality assurance. The market is expected to continue evolving, with a focus on improving test accuracy and reducing the prozone and postzone effects.

Request Free Sample

The Hospitals and blood banks segment was valued at USD 424.40 million in 2019 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 49% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market

The global ABO blood type test kit market is experiencing robust growth, driven by the increasing prevalence of blood transfusions and the rising incidence of blood-related disorders. The market's expansion is further fueled by advancements in diagnostic technologies, leading to more accurate and rapid testing methods. Stringent regulatory frameworks concerning blood safety and transfusion practices are also contributing to market growth. While precise market size figures for 2025 are unavailable, considering a conservative Compound Annual Growth Rate (CAGR) of 5% and a plausible 2019 market size of approximately $1 billion (based on typical growth rates observed in comparable diagnostic markets), the 2025 market size could be estimated at around $1.34 billion. The market is segmented based on test type (slide, tube, microplate), end-user (hospitals, blood banks, diagnostic centers), and region. Key players like DiaMed GmbH, Ortho-Clinical Diagnostics, and Immucor are shaping the market with their innovative products and extensive distribution networks. The competitive landscape is characterized by both established players and emerging companies vying for market share. Geographic expansion and strategic partnerships remain significant strategies for market growth. However, the market faces certain restraints, including the high cost of sophisticated testing equipment and the potential for inaccurate results due to human error in manual testing methods. Furthermore, the availability of skilled technicians and the need for continuous training contribute to the overall cost and complexity of maintaining high-quality testing protocols. Despite these challenges, the long-term outlook remains positive, driven by advancements in automation and the rising adoption of point-of-care testing, increasing accessibility and efficiency. Emerging markets in Asia-Pacific and Latin America are expected to show significant growth potential, providing further opportunities for expansion. The continued focus on improving blood safety standards and increasing awareness of the importance of accurate blood typing worldwide will fuel market growth in the coming years.

The global blood grouping and phenotyping reagents market is experiencing robust growth, driven by the increasing prevalence of blood-related disorders, expanding blood transfusion services, and the rising demand for accurate blood typing in various healthcare settings. The market is segmented by application (hospital, blood bank, R&D, others) and type (blood phenotyping reagents, blood grouping reagents). Hospitals and blood banks constitute the largest segments, reflecting the crucial role of accurate blood typing in safe blood transfusions and patient care. The increasing adoption of advanced technologies like automated blood typing systems and the growing focus on personalized medicine are further fueling market expansion. Research and development activities are also contributing significantly, with ongoing efforts to improve reagent accuracy, sensitivity, and efficiency. While the market faces constraints such as stringent regulatory approvals and the high cost of advanced reagents, the overall outlook remains positive, projecting substantial growth in the coming years. We estimate the 2025 market size to be approximately $2.5 billion, based on market trends and the available information. A conservative CAGR of 7% is projected for the forecast period (2025-2033), resulting in significant market expansion by 2033. Geographic regions like North America and Europe currently hold a significant market share, owing to well-established healthcare infrastructure and higher adoption rates. However, emerging economies in Asia-Pacific are expected to exhibit accelerated growth due to rising healthcare expenditure and increasing awareness about blood transfusion safety. The competitive landscape is characterized by the presence of both established multinational corporations and smaller specialized players. Companies are focusing on strategic partnerships, mergers and acquisitions, and product innovation to enhance their market position. The development of novel reagents with improved functionalities and automation capabilities will be key to sustaining competitive advantage in the future. The rising demand for point-of-care testing and the development of rapid diagnostic tests are also expected to shape the future of the blood grouping and phenotyping reagents market. This demand for faster, more efficient solutions underscores the ongoing efforts to improve blood typing technologies and streamline processes within hospitals and blood banks. The overall market trajectory indicates a significant growth opportunity for stakeholders involved in the manufacturing, distribution, and application of blood grouping and phenotyping reagents.

Blood Group Typing Technology Market Outlook

The global blood group typing technology market size was valued at approximately USD 2.8 billion in 2023 and is projected to reach USD 5.6 billion by 2032, growing at a CAGR of 7.2% during the forecast period. This robust growth is primarily driven by the increasing prevalence of chronic diseases, the growth of surgical procedures, and the rising number of blood donations and transfusions worldwide.

One of the primary growth factors for the blood group typing technology market is the escalating number of surgeries and organ transplants, which necessitate precise blood typing to ensure compatibility and reduce the risk of complications. The World Health Organization (WHO) estimates that around 310 million major surgeries are performed annually across the globe, with a significant portion requiring blood transfusions. This has amplified the demand for accurate blood group typing solutions, thereby fueling market growth.

Another significant driver is the rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes, which often require blood transfusions as part of treatment protocols. According to the International Diabetes Federation, about 463 million adults were living with diabetes globally in 2019, and this number is expected to rise to 700 million by 2045. This increasing patient pool directly correlates with the demand for blood group typing technologies, thus boosting market growth.

Technological advancements and innovations in blood group typing methodologies also contribute to market expansion. The development and adoption of advanced techniques such as PCR-based and microarray-based blood typing have significantly improved the accuracy, speed, and reliability of blood group testing. These technological advancements not only enhance the efficiency of blood typing processes but also reduce the likelihood of errors, thereby increasing their adoption across various healthcare settings.

The advent of Single Blood Drop technology is revolutionizing the landscape of blood group typing. This innovative approach allows for the determination of blood type using just a single drop of blood, significantly reducing the amount of sample needed for testing. This is particularly beneficial in situations where blood volume is limited, such as in neonatal care or when dealing with patients with anemia. The efficiency of using a Single Blood Drop not only speeds up the testing process but also minimizes discomfort for patients, making it a preferred choice in many healthcare settings. As this technology continues to evolve, it is expected to play a crucial role in enhancing the accessibility and convenience of blood group typing, thereby supporting the market's growth.

Regionally, North America holds the largest share of the blood group typing technology market, driven by the presence of a well-established healthcare infrastructure, high healthcare expenditure, and the increasing prevalence of chronic diseases. Europe follows closely, with significant contributions from countries such as Germany, France, and the UK. The Asia Pacific region is anticipated to witness the highest growth rate during the forecast period, attributed to the rising healthcare investments, growing awareness about blood donation, and improving healthcare facilities in countries like China and India.

Product Type Analysis

The blood group typing technology market is segmented by product type into consumables, instruments, and services. Consumables, which include reagents, antisera, and test kits, hold a substantial market share due to their recurring need in blood typing procedures. The continuous demand for consumables for testing in hospitals, blood banks, and diagnostic laboratories sustains this segment's growth. Moreover, advancements in consumable products that enhance the accuracy and speed of blood group typing are further propelling the segment forward.

Instruments used in blood group typing, such as automated systems and analyzers, constitute another critical segment of the market. These instruments have gained popularity due to their ability to deliver quick and precise results, reducing human error and increasing operational efficiency. The integration of advanced technologies into these instruments, such as automated data management and connectivity features, has made them indispensable in modern healthcare settings. The high initial cost of t